Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"

From Libre Pathology
Jump to navigation Jump to search
Line 4: Line 4:
==General==
==General==
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref>
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref>
*Respond to target therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref>
*Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |vauthors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref>


==Microscopic==
==Microscopic==

Revision as of 15:21, 31 December 2019

Micrograph showing a ROS1-positive adenocarcinoma of the lung. ROS1 immunostain.

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]

General

Microscopic

Features:

Note:

  • Most common pattern varies by specimen type:[4]
    • Biopsy specimens: solid pattern most common.
    • Resection specimens: acinar pattern most common.

Images

  • NSmCC - low mag.

  • NSmCC - intermed. mag.

  • NSmCC - high mag.

  • NSmCC - very high mag.

  • NSmCC - TTF-1 - high mag.

  • NSmCC - napsin A - high mag.

IHC

  • ROS1 +ve.

Images

  • NSmCC - ROS1 - low mag.

  • NSmCC - ROS1 - intermed. mag.

  • NSmCC - ROS1 -high mag.

Molecular

  • ROS1 rearrangements can be demonstrated dual-colour break apart FISH probes.[5]

See also

References

  1. ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  2. ↑ "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
  3. ↑ "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
  4. ↑ 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
  5. ↑ "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. November 2016. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.
Retrieved from "https://librepathology.org/w/index.php?title=ROS1-rearranged_non-small_cell_lung_carcinoma&oldid=50619"